The “Global Myasthenia Gravis Market: Size, Trends & Forecasts (2017-2021)” report has been added to Research and Markets’ offering.
Global Myasthenia Gravis Market: Size, Trends & Forecasts (2017-2021) provides a detailed analysis of the myasthenia gravis market with description of market size and growth. The analysis includes market size in terms of value, and market share on the basis of therapy, by cases and by severity.
The report also provides a brief regional analysis of the US. The analysis includes market size in terms of number of patients on the basis of types of myasthenia gravis. Geographically, the Americas were the largest market and is expected to dominate the market in the forecasted period also. The growth in the market is estimated on the back of rising elderly population in the region.
Furthermore, the report also assesses the key opportunities available in the market and outlines the market dynamics that are and will be accountable for growth of the industry. Growth of the global myasthenia gravis market has also been forecasted for the period 2017-2021, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends.
Some of the prominent players of the market include Avadel Pharmaceuticals, Hoffmann-La Roche, Pfizer, and Argenx. A brief company profiling of these major players have also been provided in the report on the basis of aspects like business overview, financial overview and business strategies adopted by respective companies.
Company Coverage
– Avadel Pharmaceuticals
– F. Hoffmann-La Roche
– Pfizer
– Argenx
Key Topics Covered:
1. Executive Summary
2. Introduction
2.1 Overview of Myasthenia Gravis
2.1.1 Myasthenia Gravis Statistics
2.1.2 Myasthenia Gravis Classification
2.1.3 Symptoms of Myasthenia Gravis
2.1.4 Causes of Myasthenia Gravis
2.1.5 Treatment Types for Myasthenia Gravis
3. Global Market Analysis
3.1 Global Myasthenia Gravis Market Analysis
3.1.1 Global Myasthenia Gravis Drugs Market by Value
3.1.2 Global Myasthenia Gravis Market by Therapy
3.1.3 Global Myasthenia Gravis Market by Cases
3.1.4 Global Myasthenia Gravis Cases by Severity
4. Regional Analysis
4.1 The US Myasthenia Gravis Market Analysis
4.1.1 The US Myasthenia Gravis Market by Total Patient Volume
4.1.2 The US Myasthenia Gravis Market by 2nd Line Patient Volume
4.1.3 The US Myasthenia Gravis Market by 3rd Line Severe Chronic Refractory Patient Volume
4.1.4 The US Myasthenia Gravis Market by Crisis Patient Volume
5. Market Dynamics
5.1 Growth Drivers
5.1.1 Rising Prevalence of Disease
5.1.2 Technological Advancements
5.1.3 Rising Geriatric Population
5.2 Challenges
5.2.1 Competition from Off-Label Drugs
5.2.2 Limited Availability of FDA Approved Drugs
5.2.3 High Cost
5.3 Market Trends
5.3.1 Emergence of New Entrants
5.3.2 Growing Number of Mergers and Acquisitions
5.3.3 Approval of Novel Monoclonal Antibodies
6. Competitive Landscape
6.1 The US Myasthenia Gravis Market Players by Product Comparison
7. Company Profiling
For more information about this report visit https://www.researchandmarkets.com/research/md8s9j/global_myasthenia